Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Emergency Use Authorization for MatMaCorp Coronavirus Test

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by MatMaCorp.

The MatMaCorp COVID-19 2SF Test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens including nasopharyngeal swabs and anterior nasal swabs collected by a healthcare provider.

The test runs on the Lincoln, Nebraska-based company's Solas 8 portable nucleic acid analysis system and may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

Earlier this year, MatMaCorp received funding from the National Institutes of Health under its Rapid Acceleration of Diagnostics initiative to support the development of its SARS-CoV-2 test.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.